EGFR and hepatocellular carcinoma: Acquired lenvatinib resistance in hepatocellular carcinoma was driven by an EGFR/STAT3 axis, where STAT3 directly bound the ABCB1 promoter to upregulate P-gp and enhance drug efflux, and inhibiting either EGFR or STAT3 restored drug sensitivity [31].